Roy Buchanan
Stock Analyst at JMP Securities
(0.82)
# 3,689
Out of 4,732 analysts
45
Total ratings
28.57%
Success rate
-24.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $2.08 | +765.38% | 2 | Jan 10, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $6.16 | +435.71% | 1 | Jan 10, 2025 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Outperform | $22 → $21 | $5.25 | +300.00% | 11 | Nov 26, 2024 | |
| HOOK HOOKIPA Pharma | Maintains: Market Outperform | $24 → $7 | $1.95 | +258.97% | 2 | Nov 21, 2024 | |
| ANTX AN2 Therapeutics | Reiterates: Market Outperform | $5 | $1.27 | +293.70% | 5 | Nov 19, 2024 | |
| CVAC CureVac | Reiterates: Market Outperform | $16 | $4.10 | +290.24% | 7 | Sep 16, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Market Outperform | $4 → $5 | $3.20 | +56.25% | 5 | Aug 2, 2024 | |
| DVAX Dynavax Technologies | Maintains: Market Outperform | $25 → $27 | $12.45 | +116.87% | 5 | Nov 3, 2023 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $15 | $2.21 | +578.73% | 1 | Mar 6, 2023 | |
| ARGX argenx SE | Maintains: Market Outperform | $443 → $448 | $640.52 | -30.06% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $12.17 | +31.47% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.83 | - | 2 | Feb 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $420 | $3.30 | +12,627.27% | 1 | Sep 14, 2021 |
Inovio Pharmaceuticals
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $2.08
Upside: +765.38%
ABIVAX Société Anonyme
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $6.16
Upside: +435.71%
Enanta Pharmaceuticals
Nov 26, 2024
Reiterates: Market Outperform
Price Target: $22 → $21
Current: $5.25
Upside: +300.00%
HOOKIPA Pharma
Nov 21, 2024
Maintains: Market Outperform
Price Target: $24 → $7
Current: $1.95
Upside: +258.97%
AN2 Therapeutics
Nov 19, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $1.27
Upside: +293.70%
CureVac
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $16
Current: $4.10
Upside: +290.24%
Arbutus Biopharma
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.20
Upside: +56.25%
Dynavax Technologies
Nov 3, 2023
Maintains: Market Outperform
Price Target: $25 → $27
Current: $12.45
Upside: +116.87%
Esperion Therapeutics
Mar 6, 2023
Reiterates: Market Outperform
Price Target: $15
Current: $2.21
Upside: +578.73%
argenx SE
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $640.52
Upside: -30.06%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $12.17
Upside: +31.47%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.83
Upside: -
Sep 14, 2021
Initiates: Market Outperform
Price Target: $420
Current: $3.30
Upside: +12,627.27%